AZD8055 is a potent, selective, and orally bioavailable ATP-competitive mammalian target of rapamycin kinase inhibitor with in vitro and in vivo antitumor activity - PubMed
- ️Fri Jan 01 2010
. 2010 Jan 1;70(1):288-98.
doi: 10.1158/0008-5472.CAN-09-1751. Epub 2009 Dec 22.
Barry R Davies, Ian Hickson, Tom Harding, Sabina Cosulich, Susan E Critchlow, John P Vincent, Rebecca Ellston, Darren Jones, Patrizia Sini, Dominic James, Zoe Howard, Phillippa Dudley, Gareth Hughes, Lisa Smith, Sharon Maguire, Marc Hummersone, Karine Malagu, Keith Menear, Richard Jenkins, Matt Jacobsen, Graeme C M Smith, Sylvie Guichard, Martin Pass
Affiliations
- PMID: 20028854
- DOI: 10.1158/0008-5472.CAN-09-1751
AZD8055 is a potent, selective, and orally bioavailable ATP-competitive mammalian target of rapamycin kinase inhibitor with in vitro and in vivo antitumor activity
Christine M Chresta et al. Cancer Res. 2010.
Abstract
The mammalian target of rapamycin (mTOR) kinase forms two multiprotein complexes, mTORC1 and mTORC2, which regulate cell growth, cell survival, and autophagy. Allosteric inhibitors of mTORC1, such as rapamycin, have been extensively used to study tumor cell growth, proliferation, and autophagy but have shown only limited clinical utility. Here, we describe AZD8055, a novel ATP-competitive inhibitor of mTOR kinase activity, with an IC50 of 0.8 nmol/L. AZD8055 showed excellent selectivity (approximately 1,000-fold) against all class I phosphatidylinositol 3-kinase (PI3K) isoforms and other members of the PI3K-like kinase family. Furthermore, there was no significant activity against a panel of 260 kinases at concentrations up to 10 micromol/L. AZD8055 inhibits the phosphorylation of mTORC1 substrates p70S6K and 4E-BP1 as well as phosphorylation of the mTORC2 substrate AKT and downstream proteins. The rapamycin-resistant T37/46 phosphorylation sites on 4E-BP1 were fully inhibited by AZD8055, resulting in significant inhibition of cap-dependent translation. In vitro, AZD8055 potently inhibits proliferation and induces autophagy in H838 and A549 cells. In vivo, AZD8055 induces a dose-dependent pharmacodynamic effect on phosphorylated S6 and phosphorylated AKT at plasma concentrations leading to tumor growth inhibition. Notably, AZD8055 results in significant growth inhibition and/or regression in xenografts, representing a broad range of human tumor types. AZD8055 is currently in phase I clinical trials.
Similar articles
-
The dual mTORC1 and mTORC2 inhibitor AZD8055 has anti-tumor activity in acute myeloid leukemia.
Willems L, Chapuis N, Puissant A, Maciel TT, Green AS, Jacque N, Vignon C, Park S, Guichard S, Herault O, Fricot A, Hermine O, Moura IC, Auberger P, Ifrah N, Dreyfus F, Bonnet D, Lacombe C, Mayeux P, Bouscary D, Tamburini J. Willems L, et al. Leukemia. 2012 Jun;26(6):1195-202. doi: 10.1038/leu.2011.339. Epub 2011 Dec 6. Leukemia. 2012. PMID: 22143671
-
Bhagwat SV, Gokhale PC, Crew AP, Cooke A, Yao Y, Mantis C, Kahler J, Workman J, Bittner M, Dudkin L, Epstein DM, Gibson NW, Wild R, Arnold LD, Houghton PJ, Pachter JA. Bhagwat SV, et al. Mol Cancer Ther. 2011 Aug;10(8):1394-406. doi: 10.1158/1535-7163.MCT-10-1099. Epub 2011 Jun 14. Mol Cancer Ther. 2011. PMID: 21673091
-
Luchman HA, Stechishin OD, Nguyen SA, Lun XQ, Cairncross JG, Weiss S. Luchman HA, et al. Clin Cancer Res. 2014 Nov 15;20(22):5756-67. doi: 10.1158/1078-0432.CCR-13-3389. Epub 2014 Oct 14. Clin Cancer Res. 2014. PMID: 25316808
-
Benefits of mTOR kinase targeting in oncology: pre-clinical evidence with AZD8055.
Marshall G, Howard Z, Dry J, Fenton S, Heathcote D, Gray N, Keen H, Logie A, Holt S, Smith P, Guichard SM. Marshall G, et al. Biochem Soc Trans. 2011 Apr;39(2):456-9. doi: 10.1042/BST0390456. Biochem Soc Trans. 2011. PMID: 21428919 Review.
-
RES-529: a PI3K/AKT/mTOR pathway inhibitor that dissociates the mTORC1 and mTORC2 complexes.
Weinberg MA. Weinberg MA. Anticancer Drugs. 2016 Jul;27(6):475-87. doi: 10.1097/CAD.0000000000000354. Anticancer Drugs. 2016. PMID: 26918392 Free PMC article. Review.
Cited by
-
A molecular rheostat at the interface of cancer and diabetes.
Osman MA, Sarkar FH, Rodriguez-Boulan E. Osman MA, et al. Biochim Biophys Acta. 2013 Aug;1836(1):166-76. doi: 10.1016/j.bbcan.2013.04.005. Epub 2013 Apr 29. Biochim Biophys Acta. 2013. PMID: 23639840 Free PMC article. Review.
-
Autophagy modulation as a target for anticancer drug discovery.
Li X, Xu HL, Liu YX, An N, Zhao S, Bao JK. Li X, et al. Acta Pharmacol Sin. 2013 May;34(5):612-24. doi: 10.1038/aps.2013.23. Epub 2013 Apr 8. Acta Pharmacol Sin. 2013. PMID: 23564085 Free PMC article. Review.
-
Gremke N, Polo P, Dort A, Schneikert J, Elmshäuser S, Brehm C, Klingmüller U, Schmitt A, Reinhardt HC, Timofeev O, Wanzel M, Stiewe T. Gremke N, et al. Nat Commun. 2020 Sep 17;11(1):4684. doi: 10.1038/s41467-020-18504-7. Nat Commun. 2020. PMID: 32943635 Free PMC article.
-
mTOR kinase inhibitors as potential cancer therapeutic drugs.
Sun SY. Sun SY. Cancer Lett. 2013 Oct 28;340(1):1-8. doi: 10.1016/j.canlet.2013.06.017. Epub 2013 Jun 20. Cancer Lett. 2013. PMID: 23792225 Free PMC article. Review.
-
Schuster K, Zheng J, Arbini AA, Zhang CC, Scaglioni PP. Schuster K, et al. Blood Cancer J. 2011 Sep;1(9):e34. doi: 10.1038/bcj.2011.30. Epub 2011 Sep 2. Blood Cancer J. 2011. PMID: 22829195 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
Miscellaneous